A Robust DIA-Based Platform for Large-Scale Plasma Glycoproteomics and Biomarker Discovery
The platform successfully identified glycoform-specific changes and distinguished between noncancer individuals and those with stage III/IV lung cancer, establishing a high-throughput DIA-based glycoproteomics workflow suitable for large-cohort studies to discover glycopeptide biomarker candidates.